Nintedanib in idiopathic pulmonary fibrosis: Practical management recommendations for potential adverse events

Respiration

Volumn 97, Issue 2, 2019, Pages 173-184

  Bendstrup, Elisabeth ^a   Wuyts, Wim ^b,c   Alfaro, Tiago ^d   Chaudhuri, Nazia ^e   Cornelissen, Robin ^f   Kreuter, Michael ^g   Melgaard Nielsen, Kirsten ^a   Münster, Anna Marie B ^h   Myllärniemi, Marjukka ⁱ   Ravaglia, Claudia ^j   Vanuytsel, Tim ^k   Wijsenbeek, Marlies ^l  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j MORGAGNI PIERANTONI HOSPITAL   (Italy)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Expert opinion; Idiopathic pulmonary fibrosis; Nintedanib; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NINTEDANIB; FIBRINOLYTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BLEEDING; BRONCHITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER INJURY; LUNG TRANSPLANTATION; MAJOR ADVERSE CARDIAC EVENT; MEDICATION COMPLIANCE; NAUSEA; PATIENT CARE; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; VALVULAR HEART DISEASE; VOMITING; COMPLICATION; TOXIC HEPATITIS;

CARDIOVASCULAR DISEASES; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMORBIDITY; DIARRHEA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PROTEIN KINASE INHIBITORS;

EID: 85058787445     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000495046     Document Type: Review

References (47)

1. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis Respir Med. 2014 Apr; 108(4): 647-53.
2. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respir Res. 2017 Jul; 18(1): 139.
3. Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, et al. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology. 2017 Jul; 22(5): 950-6.
4. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May; 370(22): 2083-92.
5. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(® ) trials. Respir Med. 2016 Apr; 113: 74-9.
6. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al.; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul; 192(2):e3-19.
7. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb; 183(4): 431-40.
8. Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014 Mar; 145(3): 579-85.
9. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995 Aug; 311(7001): 376-80.
10. Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis. 2017 Aug; 20(3): 359-72.
11. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun; 68(12): 4774-82.
12. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014 May; 349(2): 209-20.
13. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011 Sep; 365(12): 1079-87.
14. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May; 370(22): 2071-82.
15. European Medicines Agency: Ofev (nintedanib) soft capsules: EU summary of product characteristics, 2015.
16. Fukihara J, Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016 Dec; 10(12): 1247-54.
17. Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep; 16(1): 116.
18. Camilleri M, Sellin JH, Barrett KE. Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology. 2017 Feb; 152(3): 515-532.e2.
19. Maher TM, Inoue Y, Case AH, Sakamoto W, Stowasser S, Wuyts WA. Effect Of Dose Reductions And/or Interruptions On The Efficacy Of Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (IPF): Subgroup Analysis Of The Inpulsis Trials: American Thoracic Society 2017 International Conference. Washington DC. Am J Respir Crit Care Med. 2017; 195:A5381.
20. Noth I, Oelberg D, Kaul M, Conoscenti CS, Raghu G. Safety and tolerability of nintedanib in patients with IPF in the United States. Eur Respir J. 2018. https://doi.org/10.1183/13993003.02106-2017.
21. Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece. Pulm Pharmacol Ther. 2018 Apr; 49: 61-6.
22. Brunnemer E, Walscher J, Tenenbaum S, Hausmanns J, Schulze K, Seiter M, et al. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018; 95(5): 301-9.; Epub ahead of print.
23. Toellner H, Hughes G, Beswick W, Crooks MG, Donaldson C, Forrest I, et al. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med. 2017 Nov; 6(1): 41.
24. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One. 2016 Mar; 11(3):e0151425.
25. Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllarniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017 Dec; 3(4): 00084-02017.
26. Hilberg F, Tontsch-Grunt U, Baum A, Le AT, Doebele RC, Lieb S, et al. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther. 2018 Mar; 364(3): 494-503.
27. Tandon K, Herrmann F, Ayaub E, Parthasarathy P, Ackermann M, Inman MD, et al. Nintedanib Attenuates the Polarization of Profibrotic Macrophages Through the Inhibition of Tyrosine Phosphorylation on CSF1 Receptor: American Thoracic Society 2017 International Conference. Washington DC. Am J Respir Crit Care Med. 2017; 195:A2397.
28. Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB, et al. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer. 2016 Jan; 122(1): 124-30.
29. Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, et al. Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. BioMed Res Int. 2015; 2015: 138148.
30. Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, et al. Investigational therapies up to Phase II which target PDGF receptors: Potential anti-cancer therapeutics. Expert Opin Investig Drugs. 2015 May; 24(5): 673-87.
31. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008 May; 3(2): 132-43.
32. Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials.: American Thoracic Society 2017 International Conference. Washing-ton DC. Am J Respir Crit Care Med. 2017; 195:A5383.
33. Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2018 Sep;S2213-2600(18)30339-4.
34. Eisen T, Shparyk Y, Macleod N, Jones R, Wallenstein G, Temple G, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an openlabel, phase II study. Invest New Drugs. 2013 Oct; 31(5): 1283-93.
35. Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N. Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med. 2016 Sep; 5(9): 5.
36. Reck M, Mellemgaard A, von Pawel J, Gottfried M, Bondarenko I, Cheng Y, et al.; LUME-Lung 1 Study Group. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung Cancer. 2015 Nov; 90(2): 267-73.
37. Rodriguez-Portal JA. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update. Drugs R D. 2018 Mar; 18(1): 19-25.
38. Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, et al. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J. 2016 Jun; 47(6): 1776-84.
39. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan; 39(3): 213-60.
40. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jul; 186(1): 88-95.
41. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum. 2009 Nov; 60(11): 3455-64.
42. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol. 2001 Oct; 159(4): 1383-95.
43. Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest. 2009 Sep; 119(9): 2550-63.
44. von Suesskind-Schwendi M, Boxhammer E, Hirt SW, Schreml S, Schmid C, Wollin L, et al. The activity of nintedanib in an animal model of allogenic left lung transplantation resembling aspects of allograft rejection. Exp Lung Res. 2017 Aug-Sep; 43(6-7): 259-70.
45. Delanote I, Wuyts WA, Yserbyt J, Verbeken EK, Verleden GM, Vos R. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: A case series. BMC Pulm Med. 2016 Nov; 16(1): 156.
46. Balestro E, Solidoro P, Parigi P, Boffini M, Lucianetti A, Rea F. Safety of nintedanib before lung transplant: An Italian case series. Respirol Case Rep. 2018 Mar; 6(4):e00312.
47. Leuschner G, Stocker F, Veit T, Kneidinger N, Winter H, Schramm R, et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. 2017 Jul; 37(2): 268-74.